vs
AVANOS MEDICAL, INC.（AVNS）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
GIBRALTAR INDUSTRIES, INC.的季度营收约是AVANOS MEDICAL, INC.的1.2倍（$225.0M vs $180.9M），GIBRALTAR INDUSTRIES, INC.同比增速更快（24.9% vs 0.7%），GIBRALTAR INDUSTRIES, INC.自由现金流更多（$26.2M vs $21.3M），过去两年AVANOS MEDICAL, INC.的营收复合增速更高（4.4% vs -12.3%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
AVNS vs ROCK — 直观对比
营收规模更大
ROCK
是对方的1.2倍
$180.9M
营收增速更快
ROCK
高出24.2%
0.7%
自由现金流更多
ROCK
多$4.9M
$21.3M
两年增速更快
AVNS
近两年复合增速
-12.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $225.0M |
| 净利润 | $-1.3M | — |
| 毛利率 | 47.5% | 25.3% |
| 营业利润率 | 1.4% | 7.9% |
| 净利率 | -0.7% | — |
| 营收同比 | 0.7% | 24.9% |
| 净利润同比 | 99.7% | — |
| 每股收益（稀释后） | $-0.02 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSROCK
| Q4 25 | $180.9M | $225.0M | ||
| Q3 25 | $177.8M | $310.9M | ||
| Q2 25 | $175.0M | $309.5M | ||
| Q1 25 | $167.5M | $290.0M | ||
| Q4 24 | $179.6M | $180.1M | ||
| Q3 24 | $170.4M | $277.1M | ||
| Q2 24 | $171.7M | $273.6M | ||
| Q1 24 | $166.1M | $292.5M |
净利润AVNSROCK
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $-89.1M | ||
| Q2 25 | $-76.8M | $26.0M | ||
| Q1 25 | $6.6M | $21.1M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | $34.0M | ||
| Q2 24 | $1.8M | $32.2M | ||
| Q1 24 | $-900.0K | $24.9M |
毛利率AVNSROCK
| Q4 25 | 47.5% | 25.3% | ||
| Q3 25 | 48.4% | 26.6% | ||
| Q2 25 | 52.6% | 28.4% | ||
| Q1 25 | 53.6% | 26.8% | ||
| Q4 24 | 54.6% | 29.0% | ||
| Q3 24 | 54.5% | 29.4% | ||
| Q2 24 | 55.7% | 30.5% | ||
| Q1 24 | 57.1% | 28.9% |
营业利润率AVNSROCK
| Q4 25 | 1.4% | 7.9% | ||
| Q3 25 | 0.1% | 12.8% | ||
| Q2 25 | -42.6% | 12.8% | ||
| Q1 25 | 6.1% | 8.8% | ||
| Q4 24 | -233.0% | 13.3% | ||
| Q3 24 | 7.0% | 15.6% | ||
| Q2 24 | 3.7% | 14.9% | ||
| Q1 24 | 2.4% | 10.8% |
净利率AVNSROCK
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | -28.6% | ||
| Q2 25 | -43.9% | 8.4% | ||
| Q1 25 | 3.9% | 7.3% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | 12.3% | ||
| Q2 24 | 1.0% | 11.8% | ||
| Q1 24 | -0.5% | 8.5% |
每股收益（稀释后）AVNSROCK
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.03 | $-2.98 | ||
| Q2 25 | $-1.66 | $0.87 | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | — | ||
| Q3 24 | $0.09 | $1.11 | ||
| Q2 24 | $0.04 | $1.05 | ||
| Q1 24 | $-0.02 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $115.7M |
| 总债务越低越好 | $90.3M | $0 |
| 股东权益账面价值 | $778.2M | $950.4M |
| 总资产 | $1.1B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.12× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资AVNSROCK
| Q4 25 | $89.8M | $115.7M | ||
| Q3 25 | $70.5M | $89.4M | ||
| Q2 25 | $90.3M | $43.3M | ||
| Q1 25 | $97.0M | $25.1M | ||
| Q4 24 | $107.7M | $269.5M | ||
| Q3 24 | $89.0M | $228.9M | ||
| Q2 24 | $92.2M | $179.1M | ||
| Q1 24 | $75.8M | $146.7M |
总债务AVNSROCK
| Q4 25 | $90.3M | $0 | ||
| Q3 25 | $93.4M | $0 | ||
| Q2 25 | $95.7M | $0 | ||
| Q1 25 | $98.0M | $0 | ||
| Q4 24 | $125.3M | $0 | ||
| Q3 24 | $152.6M | $0 | ||
| Q2 24 | $164.9M | $0 | ||
| Q1 24 | $167.2M | $0 |
股东权益AVNSROCK
| Q4 25 | $778.2M | $950.4M | ||
| Q3 25 | $778.0M | $951.8M | ||
| Q2 25 | $776.3M | $1.0B | ||
| Q1 25 | $839.4M | $1.0B | ||
| Q4 24 | $828.5M | $1.0B | ||
| Q3 24 | $1.2B | $1.0B | ||
| Q2 24 | $1.2B | $975.7M | ||
| Q1 24 | $1.2B | $940.2M |
总资产AVNSROCK
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.2B | $1.4B | ||
| Q3 24 | $1.7B | $1.4B | ||
| Q2 24 | $1.7B | $1.4B | ||
| Q1 24 | $1.7B | $1.3B |
负债/权益比AVNSROCK
| Q4 25 | 0.12× | 0.00× | ||
| Q3 25 | 0.12× | 0.00× | ||
| Q2 25 | 0.12× | 0.00× | ||
| Q1 25 | 0.12× | 0.00× | ||
| Q4 24 | 0.15× | 0.00× | ||
| Q3 24 | 0.12× | 0.00× | ||
| Q2 24 | 0.13× | 0.00× | ||
| Q1 24 | 0.14× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $35.5M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $26.2M |
| 自由现金流率自由现金流/营收 | 11.8% | 11.7% |
| 资本支出强度资本支出/营收 | 3.8% | 4.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | $120.6M |
8季度趋势，按日历期对齐
经营现金流AVNSROCK
| Q4 25 | $28.2M | $35.5M | ||
| Q3 25 | $14.0M | $73.0M | ||
| Q2 25 | $6.8M | $44.9M | ||
| Q1 25 | $25.7M | $13.7M | ||
| Q4 24 | $57.9M | $19.9M | ||
| Q3 24 | $23.0M | $64.7M | ||
| Q2 24 | $27.8M | $36.5M | ||
| Q1 24 | $-8.0M | $53.2M |
自由现金流AVNSROCK
| Q4 25 | $21.3M | $26.2M | ||
| Q3 25 | $7.0M | $64.8M | ||
| Q2 25 | $-4.2M | $27.3M | ||
| Q1 25 | $19.0M | $2.3M | ||
| Q4 24 | $53.1M | $14.1M | ||
| Q3 24 | $20.0M | $60.5M | ||
| Q2 24 | $21.9M | $33.5M | ||
| Q1 24 | $-12.1M | $48.8M |
自由现金流率AVNSROCK
| Q4 25 | 11.8% | 11.7% | ||
| Q3 25 | 3.9% | 20.8% | ||
| Q2 25 | -2.4% | 8.8% | ||
| Q1 25 | 11.3% | 0.8% | ||
| Q4 24 | 29.6% | 7.8% | ||
| Q3 24 | 11.7% | 21.8% | ||
| Q2 24 | 12.8% | 12.2% | ||
| Q1 24 | -7.3% | 16.7% |
资本支出强度AVNSROCK
| Q4 25 | 3.8% | 4.1% | ||
| Q3 25 | 3.9% | 2.6% | ||
| Q2 25 | 6.3% | 5.7% | ||
| Q1 25 | 4.0% | 3.9% | ||
| Q4 24 | 2.7% | 3.3% | ||
| Q3 24 | 1.8% | 1.5% | ||
| Q2 24 | 3.4% | 1.1% | ||
| Q1 24 | 2.5% | 1.5% |
现金转化率AVNSROCK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.73× | ||
| Q1 25 | 3.89× | 0.65× | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | 1.90× | ||
| Q2 24 | 15.44× | 1.13× | ||
| Q1 24 | — | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
